Guidance for the treatment of neovascular age‐related macular degeneration

摘要: Neovascular age-related macular degeneration is becoming an increasing socio-medical problem as the proportion of aged population continuously increasing. However, new insights in pathogenesis disease offer opportunity to develop targeted therapies that attack process more successfully than ever. This review article will focus on summarizing actual options management neovascular and provide a short overview about recent therapeutic clinical preclinical evaluation. The development anti-VEGF substances for use routine has markedly improved prognosis patients with AMD. Intravitreal treatment targeting all isotypes vascular endothelial growth factor (VEGF), first time history AMD treatments, results significant increase visual acuity Overall, antiangiogenic approaches vision maintenance over 90% substantial improvement 25-40% patients. combination occlusive like photodynamic therapy (PDT) potentially offers reduction re-treatment frequency long-term benefit. Further developments interacting various steps angiogenic cascade are under or evaluation may soon become available. Nevertheless, growing number novel have proof concept randomized controlled trials, major challenge view rapidly evolving field. For those therapies, which already use, reasonable diagnostic tools follow-up need be developed, burden continuous monitoring indications doctors. Ultimately, economic issues limiting availability different options.